Diaceutics (DXRX) Competitors

Diaceutics logo
GBX 182 -8.00 (-4.21%)
As of 11/20/2026 12:33 PM Eastern

DXRX vs. ABDX, YGEN, GDR, VRCI, and AGL

Should you buy Diaceutics stock or one of its competitors? Diaceutics's main competitors and comparable companies include Abingdon Health (ABDX), Yourgene Health (YGEN), genedrive (GDR), Verici Dx (VRCI), and ANGLE (AGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Diaceutics compare to Abingdon Health?

Abingdon Health (LON:ABDX) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

0.8% of Abingdon Health shares are held by institutional investors. Comparatively, 32.2% of Diaceutics shares are held by institutional investors. 5.4% of Abingdon Health shares are held by insiders. Comparatively, 26.2% of Diaceutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Abingdon Health has a beta of 0.132, indicating that its share price is 87% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.884, indicating that its share price is 12% less volatile than the broader market.

Abingdon Health has higher earnings, but lower revenue than Diaceutics. Diaceutics is trading at a lower price-to-earnings ratio than Abingdon Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abingdon Health£10.99M3.30-£796.37K-£0.51N/A
Diaceutics£41.33M3.74-£2.84M-£0.32N/A

Diaceutics has a net margin of -0.66% compared to Abingdon Health's net margin of -19.36%. Diaceutics' return on equity of -0.68% beat Abingdon Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Abingdon Health-19.36% -34.31% -17.93%
Diaceutics -0.66%-0.68%-6.06%

In the previous week, Diaceutics had 2 more articles in the media than Abingdon Health. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for Abingdon Health. Abingdon Health's average media sentiment score of 0.00 beat Diaceutics' score of -0.92 indicating that Abingdon Health is being referred to more favorably in the media.

Company Overall Sentiment
Abingdon Health Neutral
Diaceutics Negative

Diaceutics has a consensus price target of GBX 215, suggesting a potential upside of 18.13%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts plainly believe Diaceutics is more favorable than Abingdon Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abingdon Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Diaceutics beats Abingdon Health on 13 of the 16 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.884, indicating that its stock price is 12% less volatile than the broader market.

Diaceutics has higher revenue and earnings than Yourgene Health. Diaceutics is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yourgene Health£29.67M0.00-£8.17M-£0.01N/A
Diaceutics£41.33M3.74-£2.84M-£0.32N/A

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 32.2% of Diaceutics shares are held by institutional investors. 64.4% of Yourgene Health shares are held by insiders. Comparatively, 26.2% of Diaceutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Diaceutics has a net margin of -0.66% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of -0.68% beat Yourgene Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Yourgene Health-27.55% -27.06% -6.71%
Diaceutics -0.66%-0.68%-6.06%

Diaceutics has a consensus target price of GBX 215, suggesting a potential upside of 18.13%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Yourgene Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yourgene Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Diaceutics had 2 more articles in the media than Yourgene Health. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for Yourgene Health. Yourgene Health's average media sentiment score of 0.00 beat Diaceutics' score of -0.92 indicating that Yourgene Health is being referred to more favorably in the media.

Company Overall Sentiment
Yourgene Health Neutral
Diaceutics Negative

Summary

Diaceutics beats Yourgene Health on 11 of the 15 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

Diaceutics (LON:DXRX) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, Diaceutics had 2 more articles in the media than genedrive. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for genedrive. genedrive's average media sentiment score of 0.67 beat Diaceutics' score of -0.92 indicating that genedrive is being referred to more favorably in the news media.

Company Overall Sentiment
Diaceutics Negative
genedrive Positive

Diaceutics has a beta of 0.884, meaning that its stock price is 12% less volatile than the broader market. Comparatively, genedrive has a beta of 1.004, meaning that its stock price is 0% more volatile than the broader market.

32.2% of Diaceutics shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 26.2% of Diaceutics shares are held by insiders. Comparatively, 28.1% of genedrive shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Diaceutics currently has a consensus target price of GBX 215, indicating a potential upside of 18.13%. Given Diaceutics' stronger consensus rating and higher possible upside, research analysts plainly believe Diaceutics is more favorable than genedrive.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
genedrive
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Diaceutics has higher revenue and earnings than genedrive. Diaceutics is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diaceutics£41.33M3.74-£2.84M-£0.32N/A
genedrive£929K14.43-£21.22M-£0.79N/A

Diaceutics has a net margin of -0.66% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of -0.68% beat genedrive's return on equity.

Company Net Margins Return on Equity Return on Assets
Diaceutics-0.66% -0.68% -6.06%
genedrive -500.75%-1,044.57%-74.09%

Summary

Diaceutics beats genedrive on 11 of the 16 factors compared between the two stocks.

How does Diaceutics compare to Verici Dx?

Verici Dx (LON:VRCI) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

9.9% of Verici Dx shares are held by institutional investors. Comparatively, 32.2% of Diaceutics shares are held by institutional investors. 1.1% of Verici Dx shares are held by insiders. Comparatively, 26.2% of Diaceutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Diaceutics has a net margin of -0.66% compared to Verici Dx's net margin of -223.60%. Diaceutics' return on equity of -0.68% beat Verici Dx's return on equity.

Company Net Margins Return on Equity Return on Assets
Verici Dx-223.60% -127.57% -26.14%
Diaceutics -0.66%-0.68%-6.06%

Verici Dx has a beta of 1.222, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Diaceutics has a beta of 0.884, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, Diaceutics had 2 more articles in the media than Verici Dx. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for Verici Dx. Verici Dx's average media sentiment score of 0.00 beat Diaceutics' score of -0.92 indicating that Verici Dx is being referred to more favorably in the media.

Company Overall Sentiment
Verici Dx Neutral
Diaceutics Negative

Diaceutics has a consensus price target of GBX 215, suggesting a potential upside of 18.13%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Verici Dx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verici Dx
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Diaceutics has higher revenue and earnings than Verici Dx. Diaceutics is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verici Dx£3.52M3.37-£6.56M£0.101.78
Diaceutics£41.33M3.74-£2.84M-£0.32N/A

Summary

Diaceutics beats Verici Dx on 12 of the 16 factors compared between the two stocks.

How does Diaceutics compare to ANGLE?

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Diaceutics has a net margin of -0.66% compared to ANGLE's net margin of -1,560.86%. Diaceutics' return on equity of -0.68% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Diaceutics-0.66% -0.68% -6.06%
ANGLE -1,560.86%-157.49%-29.89%

In the previous week, Diaceutics had 2 more articles in the media than ANGLE. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for ANGLE. ANGLE's average media sentiment score of 0.00 beat Diaceutics' score of -0.92 indicating that ANGLE is being referred to more favorably in the news media.

Company Overall Sentiment
Diaceutics Negative
ANGLE Neutral

32.2% of Diaceutics shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 26.2% of Diaceutics shares are held by company insiders. Comparatively, 2.7% of ANGLE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Diaceutics has a beta of 0.884, indicating that its stock price is 12% less volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Diaceutics presently has a consensus price target of GBX 215, indicating a potential upside of 18.13%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than ANGLE.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ANGLE
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diaceutics£41.33M3.74-£2.84M-£0.32N/A
ANGLE£2.62M2.89-£21.76M-£4.80N/A

Summary

Diaceutics beats ANGLE on 14 of the 16 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

DXRX vs. The Competition

MetricDiaceuticsLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£154.65M£10.69B£7.78B£2.67B
Dividend YieldN/A1.46%2.47%5.11%
P/E Ratio-568.7549.0032.9322.78
Price / Sales3.748.468.104.91
Price / Cash3.1226.5521.0120.23
Price / Book3.974.194.262.40
Net Income-£2.84M£56.66B£3.50B£5.88B
1 Month Performance-9.00%-7.81%-10.48%-4.75%
1 Year Performance12.35%11.09%-4.61%5.15%

Diaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXRX
Diaceutics
1.3583 of 5 stars
GBX 182
-4.2%
GBX 215
+18.1%
+11.5%£154.65M£41.33MN/A151
ABDX
Abingdon Health
N/AGBX 9
+5.9%
N/A+19.0%£39.16M£10.99MN/A84
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67MN/A253
GDR
genedrive
N/AGBX 0.89
-1.3%
N/A-11.0%£14.26M£929KN/A43
VRCI
Verici Dx
N/AGBX 0.20
-1.0%
N/A-73.7%£13.52M£3.52M2.0319

Related Companies and Tools


This page (LON:DXRX) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners